Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Neoplasm Metastasis 4Lung Neoplasms 3Recurrence 2Brain Neoplasms 2Triple Negative Breast Neoplasms 1Neoplasms 1Head and Neck Neoplasms 1Glioblastoma 1Carcinoma 1Advanced Malignant Solid Tumors 1

Interventions

Cisplatin 75Cetuximab 63Radiotherapy 38pembrolizumab 29Radiotherapy, Intensity-Modulated 28Carboplatin 25Fluorouracil 24Docetaxel 24Paclitaxel 19Erlotinib Hydrochloride 13Nivolumab 12Radiation 10Pemetrexed 10durvalumab 8Gemcitabine 8Drug Therapy 8Bevacizumab 7zalutumumab 6Surgical Procedures, Operative 6Panitumumab 6Lapatinib 6Everolimus 6Albumin-Bound Paclitaxel 6130-nm albumin-bound paclitaxel 6epacadostat 5Standard of Care 5Oxaliplatin 5Gefitinib 5Afatinib 5Radiosurgery 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Head and Neck Neoplasms × dacomitinib × Clear all
NCT00768664 2021-02-09

Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer

Pfizer

Phase 2 Completed
69 enrolled 18 charts
Head & Neck

Head and Neck Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡